Antitumor activity of a novel EGFR tyrosine kinase inhibitor against human lung carcinoma in vitro and in vivo

[1]  A. Rossi,et al.  Three Cases of Long-Lasting Tumor Control with Erlotinib after Progression with Gefitinib in Advanced Non-Small Cell Lung Cancer , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  Hoguen Kim,et al.  Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Fukuoka,et al.  Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification. , 2007, Cancer research.

[4]  P. Jänne,et al.  Effect of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutations on the Outcome of Patients with Non–Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors , 2006, Clinical Cancer Research.

[5]  C. Bai,et al.  Potential role of short hairpin RNA targeting epidermal growth factor receptor in growth and sensitivity to drugs of human lung adenocarcinoma cells. , 2006, Biochemical pharmacology.

[6]  E. Baba,et al.  Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells , 2006, Cancer Chemotherapy and Pharmacology.

[7]  A. Jemal,et al.  Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.

[8]  E. Felip,et al.  Clinical experience with erlotinib in non-small-cell lung cancer. , 2006, Drugs of today.

[9]  E. Baba,et al.  Gefitinib, a selective EGFR tyrosine kinase inhibitor, induces apoptosis through activation of Bax in human gallbladder adenocarcinoma cells , 2006, Journal of cellular biochemistry.

[10]  Ming-Sound Tsao,et al.  A review of erlotinib and its clinical use , 2006, Expert opinion on pharmacotherapy.

[11]  K. Penne,et al.  Gefitinib (IressaTM, ZD1839) and Tyrosine Kinase Inhibitors: The Wave of the Future in Cancer Therapy , 2005, Cancer nursing.

[12]  Kevin Carroll,et al.  Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) , 2005, The Lancet.

[13]  D. Garfield.  Modern treatment of lung cancer: case 2. Response to erlotinib after failure of gefitinib in a patient with advanced non-small-cell lung carcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Janine Smith,et al.  Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer. , 2005, Clinical therapeutics.

[15]  P. Zimmerman,et al.  Approval Summary for Erlotinib for Treatment of Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer after Failure of at Least One Prior Chemotherapy Regimen , 2005, Clinical Cancer Research.

[16]  N. Taira,et al.  Antitumor effect of gefitinib ('Iressa') on esophageal squamous cell carcinoma cell lines in vitro and in vivo. , 2005, Cancer letters.

[17]  Renato Martins,et al.  Erlotinib in previously treated non-small-cell lung cancer. , 2005, The New England journal of medicine.

[18]  H. Cidade,et al.  Artelastin is a cytotoxic prenylated flavone that disturbs microtubules and interferes with DNA replication in MCF-7 human breast cancer cells. , 2005, Life sciences.

[19]  J. Rigas,et al.  Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  E. Baldi,et al.  Gefitinib (‘IRESSA’, ZD1839) inhibits EGF-induced invasion in prostate cancer cells by suppressing PI3 K/AKT activation , 2004, Journal of Cancer Research and Clinical Oncology.

[21]  T. Ganesan,et al.  Tyrosine kinase inhibitors in cancer therapy. , 2004, Clinical biochemistry.

[22]  Daniel Jones.  Anticancer drugs: To the rescue? , 2004, Nature Reviews Drug Discovery.

[23]  William Pao,et al.  Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  R. Pazdur,et al.  FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. , 2003, The oncologist.

[25]  J. Baselga,et al.  Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Masahiro Fukuoka,et al.  Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  M. Kris,et al.  Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  P. Jänne,et al.  Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. , 2002, Cancer research.

[29]  David Harrington,et al.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.

[30]  Y. Yarden.  The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. , 2001, European journal of cancer.

[31]  A. Ullrich,et al.  The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. , 2001, Endocrine-related cancer.

[32]  R. Salgia,et al.  Gefitinib response of erlotinib-refractory lung cancer involving meninges—role of EGFR mutation , 2006, Nature Clinical Practice Oncology.

[33]  D. Kerr,et al.  Single-Dose Clinical Pharmacokinetic Studies of Gefitinib , 2005, Clinical pharmacokinetics.

[34]  M. Wei,et al.  Genetic Vaccines and Therapy , 2005 .

[35]  L. Chiang,et al.  Antileukemic activity of Bidens pilosa L. var. minor (Blume) Sherff and Houttuynia cordata Thunb. , 2001, The American journal of Chinese medicine.